Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daming Zhou

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Nature Communications|March 29, 2024
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86Daming Zhou, Piyada Supasa, Chang Liu, et al.
Nature Communications|April 16, 2024
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infectionChang Liu, Raksha Das, Aiste Dijokaite-Guraliuc, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2024
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibitionRoi Asor, Anna Olerinyova, Sean A Burnap, et al.
Nature Communications|June 7, 2023
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapyManon Ragonnet-Cronin, Rungtiwa Nutalai, Jiandong Huo, et al.
Cell Host & Microbe|September 10, 2020
Neutralization of SARS-CoV-2 by Destruction of the Prefusion SpikeJiandong Huo, Yuguang Zhao, Jingshan Ren, et al.
Cell Host & Microbe|June 26, 2020
Neutralization of SARS-CoV-2 by Destruction of the Prefusion SpikeJiandong Huo, Yuguang Zhao, Jingshan Ren, et al.
Theranostics|January 6, 2022
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2Kuan-Ying A Huang, Daming Zhou, Tiong Kit Tan, et al.
Cell Reports. Medicine|May 9, 2024
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinityChang Liu, Daming Zhou, Aiste Dijokaite-Guraliuc, et al.
The Lancet. Infectious Diseases|November 25, 2023
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled studyXiaohong Fan, Xiahong Dai, Yun Ling, et al.
Cell Host & Microbe|December 18, 2021
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variantsChang Liu, Daming Zhou, Rungtiwa Nutalai, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Nature Communications|March 29, 2024
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86Daming Zhou, Piyada Supasa, Chang Liu, et al.
Nature Communications|April 16, 2024
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infectionChang Liu, Raksha Das, Aiste Dijokaite-Guraliuc, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2024
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibitionRoi Asor, Anna Olerinyova, Sean A Burnap, et al.
Nature Communications|June 7, 2023
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapyManon Ragonnet-Cronin, Rungtiwa Nutalai, Jiandong Huo, et al.
Cell Host & Microbe|September 10, 2020
Neutralization of SARS-CoV-2 by Destruction of the Prefusion SpikeJiandong Huo, Yuguang Zhao, Jingshan Ren, et al.
Cell Host & Microbe|June 26, 2020
Neutralization of SARS-CoV-2 by Destruction of the Prefusion SpikeJiandong Huo, Yuguang Zhao, Jingshan Ren, et al.
Theranostics|January 6, 2022
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2Kuan-Ying A Huang, Daming Zhou, Tiong Kit Tan, et al.
Cell Reports. Medicine|May 9, 2024
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinityChang Liu, Daming Zhou, Aiste Dijokaite-Guraliuc, et al.
The Lancet. Infectious Diseases|November 25, 2023
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled studyXiaohong Fan, Xiahong Dai, Yun Ling, et al.
Cell Host & Microbe|December 18, 2021
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variantsChang Liu, Daming Zhou, Rungtiwa Nutalai, et al.
Pageof 9